Literature DB >> 10749864

Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei.

F S Buckner1, K Yokoyama, L Nguyen, A Grewal, H Erdjument-Bromage, P Tempst, C L Strickland, L Xiao, W C Van Voorhis, M H Gelb.   

Abstract

Protein prenylation occurs in the protozoan that causes African sleeping sickness (Trypanosoma brucei), and the protein farnesyltransferase appears to be a good target for developing drugs. We have cloned the alpha- and beta-subunits of T. brucei protein farnesyltransferase (TB-PFT) using nucleic acid probes designed from partial amino acid sequences obtained from the enzyme purified from insect stage parasites. TB-PFT is expressed in both bloodstream and insect stage parasites. Enzymatically active TB-PFT was produced by heterologous expression in Escherichia coli. Compared with mammalian protein farnesyltransferases, TB-PFT contains a number of inserts of >25 residues in both subunits that reside on the surface of the enzyme in turns linking adjacent alpha-helices. Substrate specificity studies with a series of 20 peptides SSCALX (where X indicates a naturally occurring amino acid) show that the recombinant enzyme behaves identically to the native enzyme and displays distinct specificity compared with mammalian protein farnesyltransferase. TB-PFT prefers Gln and Met at the X position but not Ser, Thr, or Cys, which are good substrates for mammalian protein farnesyltransferase. A structural homology model of the active site of TB-PFT provides a basis for understanding structure-activity relations among substrates and CAAX mimetic inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749864      PMCID: PMC2913713          DOI: 10.1074/jbc.M000975200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase.

Authors:  F G Njoroge; R J Doll; B Vibulbhan; C S Alvarez; W R Bishop; J Petrin; P Kirschmeier; N I Carruthers; J K Wong; M M Albanese; J J Piwinski; J Catino; V Girijavallabhan; A K Ganguly
Journal:  Bioorg Med Chem       Date:  1997-01       Impact factor: 3.641

Review 2.  Ras farnesyltransferase: a new therapeutic target.

Authors:  D M Leonard
Journal:  J Med Chem       Date:  1997-09-12       Impact factor: 7.446

3.  Prenylation of proteins in Trypanosoma brucei.

Authors:  K Yokoyama; Y Lin; K D Stuart; M H Gelb
Journal:  Mol Biochem Parasitol       Date:  1997-07       Impact factor: 1.759

4.  Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.

Authors:  J Sun; Y Qian; A D Hamilton; S M Sebti
Journal:  Oncogene       Date:  1998-03       Impact factor: 9.867

5.  Virulence in Trypanosoma cruzi infection correlates with the expression of a distinct family of sialidase superfamily genes.

Authors:  D Weston; B Patel; W C Van Voorhis
Journal:  Mol Biochem Parasitol       Date:  1999-01-05       Impact factor: 1.759

6.  The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth.

Authors:  K Yokoyama; P Trobridge; F S Buckner; J Scholten; K D Stuart; W C Van Voorhis; M H Gelb
Journal:  Mol Biochem Parasitol       Date:  1998-07-01       Impact factor: 1.759

7.  Tubulin genes are tandemly linked and clustered in the genome of trypanosoma brucei.

Authors:  L S Thomashow; M Milhausen; W J Rutter; N Agabian
Journal:  Cell       Date:  1983-01       Impact factor: 41.582

8.  Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue.

Authors:  C L Strickland; W T Windsor; R Syto; L Wang; R Bond; Z Wu; J Schwartz; H V Le; L S Beese; P C Weber
Journal:  Biochemistry       Date:  1998-11-24       Impact factor: 3.162

9.  Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate.

Authors:  S B Long; P J Casey; L S Beese
Journal:  Biochemistry       Date:  1998-07-07       Impact factor: 3.162

10.  Protein farnesyltransferase from Trypanosoma brucei. A heterodimer of 61- and 65-kda subunits as a new target for antiparasite therapeutics.

Authors:  K Yokoyama; P Trobridge; F S Buckner; W C Van Voorhis; K D Stuart; M H Gelb
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

View more
  7 in total

Review 1.  Therapeutic intervention based on protein prenylation and associated modifications.

Authors:  Michael H Gelb; Lucas Brunsveld; Christine A Hrycyna; Susan Michaelis; Fuyuhiko Tamanoi; Wesley C Van Voorhis; Herbert Waldmann
Journal:  Nat Chem Biol       Date:  2006-10       Impact factor: 15.040

Review 2.  Benzophenone: a ubiquitous scaffold in medicinal chemistry.

Authors:  Khemchand Surana; Bharatkumar Chaudhary; Monika Diwaker; Satyasheel Sharma
Journal:  Medchemcomm       Date:  2018-08-23       Impact factor: 3.597

3.  Protein geranylgeranyltransferase-I of Trypanosoma cruzi.

Authors:  Kohei Yokoyama; John R Gillespie; Wesley C Van Voorhis; Frederick S Buckner; Michael H Gelb
Journal:  Mol Biochem Parasitol       Date:  2007-10-02       Impact factor: 1.759

4.  A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents.

Authors:  Frederick Buckner; Kohei Yokoyama; Jeffrey Lockman; Kendra Aikenhead; Junko Ohkanda; Martin Sadilek; Said Sebti; Wesley Van Voorhis; Andrew Hamilton; Michael H Gelb
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

5.  Solanesyl diphosphate synthase, an enzyme of the ubiquinone synthetic pathway, is required throughout the life cycle of Trypanosoma brucei.

Authors:  De-Hua Lai; Estefanía Poropat; Carlos Pravia; Malena Landoni; Alicia S Couto; Fernando G Pérez Rojo; Alicia G Fuchs; Marta Dubin; Igal Elingold; Juan B Rodríguez; Marcela Ferella; Mónica I Esteva; Esteban J Bontempi; Julius Lukes
Journal:  Eukaryot Cell       Date:  2013-12-27

6.  An essential farnesylated kinesin in Trypanosoma brucei.

Authors:  Erin J Engelson; Frederick S Buckner; Wesley C Van Voorhis
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

7.  Bioactivity of Farnesyltransferase Inhibitors Against Entamoeba histolytica and Schistosoma mansoni.

Authors:  Alexandra Probst; Thi N Nguyen; Nelly El-Sakkary; Danielle Skinner; Brian M Suzuki; Frederick S Buckner; Michael H Gelb; Conor R Caffrey; Anjan Debnath
Journal:  Front Cell Infect Microbiol       Date:  2019-05-29       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.